JPMorgan analyst Lisa Gill raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $180 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Balancing Strong Q1 Performance with Moderate Future Growth Outlook
- Quest Diagnostics: Strong Growth Potential and Resilience Amidst Economic Uncertainty
- Quest Diagnostics price target raised to $190 from $182 at Truist
- Quest Diagnostics price target raised to $194 from $191 at Baird
- Quest Diagnostics: Resilience and Growth Potential Amidst Macroeconomic Challenges